Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Global Blood Therapeutics, Inc.    GBT

GLOBAL BLOOD THERAPEUTICS, INC.

(GBT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

GBT to Present at the 38th Annual J.P. Morgan Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
01/07/2020 | 08:01am EST

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020, at 4:00 p.m. Pacific Time.

The presentation and Q&A session will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for replay for one month following the event.

About GBT
GBT is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta™ (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact Information:
Steven Immergut (media)
GBT
650-410-3258
media@gbt.com

Stephanie Yao (investors)
GBT
650-741-7730
investor@gbt.com

Primary Logo


© GlobeNewswire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GLOBAL BLOOD THERAPEUTICS,
02/19GBT to Announce Fourth Quarter and Full Year 2019 Financial Results on Wednes..
GL
02/03GBT Announces New Employment Inducement Grants
GL
01/09GLOBAL BLOOD THERAPEUTICS, INC. : Change in Directors or Principal Officers, Fin..
AQ
01/08GBT Announces New Employment Inducement Grants
GL
01/07GBT to Present at the 38th Annual J.P. Morgan Healthcare Conference
GL
2019Novartis wins Medicaid approval for new sickle cell drug in key U.S. states
RE
2019GLOBAL BLOOD THERAPEUTICS : GBT and Syros Partner to Discover, Develop and Comme..
AQ
2019GLOBAL BLOOD THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Cr..
AQ
2019GLOBAL BLOOD THERAPEUTICS : GBT Secures $150 Million Non-Dilutive Term Loan Fina..
AQ
2019GLOBAL BLOOD THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (fo..
AQ
More news
Financials (USD)
Sales 2019 0,52 M
EBIT 2019 -260 M
Net income 2019 -246 M
Finance 2019 561 M
Yield 2019 -
P/E ratio 2019 -16,9x
P/E ratio 2020 -15,8x
EV / Sales2019 7 152x
EV / Sales2020 79,1x
Capitalization 4 298 M
Chart GLOBAL BLOOD THERAPEUTICS, INC.
Duration : Period :
Global Blood Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLOBAL BLOOD THERAPEUTICS,
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 100,06  $
Last Close Price 71,35  $
Spread / Highest target 110%
Spread / Average Target 40,2%
Spread / Lowest Target -15,9%
EPS Revisions
Managers
NameTitle
Ted W. Love President, Chief Executive Officer & Director
Mark L. Perry Chairman
Peter Radovich Senior Vice President-Operations
Jeffrey S. Farrow Chief Financial Officer
Jonathan Sorof Senior Vice President-Medical & Regulatory affairs
Sector and Competitors
1st jan.Capitalization (M$)
GLOBAL BLOOD THERAPEUTICS, INC.-10.24%4 298
IQVIA HOLDINGS INC.6.39%31 817
LONZA GROUP18.04%31 767
SEATTLE GENETICS, INC.4.93%20 666
CELLTRION, INC.--.--%19 703
INCYTE CORPORATION-9.18%17 190